Ser210
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser210  -  GAB2 (human)

Site Information
AENARsAsFsQGTRA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 4825112

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 7 , 8 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 ) , phospho-antibody ( 18 ) , western blotting ( 18 )
Disease tissue studied:
breast cancer ( 2 , 8 , 18 ) , breast ductal carcinoma ( 2 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 , 2 ) , lung cancer ( 5 , 8 ) , non-small cell lung cancer ( 8 ) , non-small cell lung adenocarcinoma ( 5 ) , neuroblastoma ( 7 ) , pancreatic ductal adenocarcinoma ( 4 ) , teratoma ( 14 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
PIK3CA (human) ( 18 )
Treatments:
Akt-I-1,2 ( 18 ) , EGF ( 18 ) , Go_6850 ( 18 ) , Go_6976 ( 18 ) , H-89 ( 18 ) , insulin ( 18 ) , KN-62 ( 18 ) , LY294002 ( 18 ) , mPKI ( 18 ) , rapamycin ( 18 ) , U0126 ( 18 ) , wortmannin ( 18 ) , Y27632 ( 18 )

Downstream Regulation
Effects of modification on GAB2:
activity, inhibited ( 18 ) , intracellular localization ( 18 ) , molecular association, regulation ( 18 ) , phosphorylation ( 18 )
Effects of modification on biological processes:
cell growth, altered ( 18 )
Induce interaction with:
14-3-3 beta (human) ( 18 )
Inhibit interaction with:
EGFR (human) ( 18 ) , GRB2 (human) ( 18 ) , SHC1 (human) ( 18 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

3

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

4

Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948
24670416   Curated Info

5

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

6

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

7

DeNardo BD, et al. (2013) Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 8, e82513
24349301   Curated Info

8

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

9

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

10

Mulhern D (2011) CST Curation Set: 12840; Year: 2011; Biosample/Treatment: cell line, HEK 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

11

Mulhern D (2011) CST Curation Set: 12710; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP
Curated Info

12

Mulhern D (2011) CST Curation Set: 12711; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP
Curated Info

13

Mulhern D (2011) CST Curation Set: 12713; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) 14-3-3 Binding Motif Antibody Cat#: 9601
Curated Info

14

Zhou J (2010) CST Curation Set: 9672; Year: 2010; Biosample/Treatment: cell line, NCCIT/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

15

Possemato A (2009) CST Curation Set: 6906; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

16

Possemato A (2009) CST Curation Set: 6907; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXT-P) (81E12B5) Rabbit mAb Cat#: 10003
Curated Info

17

Possemato A (2009) CST Curation Set: 6896; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

18

Brummer T, et al. (2008) Phosphorylation-dependent binding of 14-3-3 terminates signalling by the Gab2 docking protein. EMBO J 27, 2305-16
19172738   Curated Info